QuantLogix's current estimate for Dyno Therapeutics, published 2026-09-27 — below the last disclosed round of $500M (2021-Q2).
Confidence
medium
Basis
secondary led
What backs this price
Last disclosed round
$500M
2021-Q2
weight 0.03
Secondary market print
$284M
2026-06-27
weight 0.58
How this price has held up
No round has priced for Dyno Therapeutics since QuantLogix began publishing a price for it, so there is nothing to grade yet. The claim above is on the record from 2026-09-27 and will be graded against the next priced round. See the full accuracy record →
Which publicly-traded funds already hold it, what $10,000 buys, and whether any route is open to you.
Cite this price as QuantLogix QL Price, Dyno Therapeutics, 2026-09-27 (340f1a3de387c04b).
The id pins this exact claim, so a citation stays checkable after the price moves.
Model estimate for research — not a quote, target price, or investment advice.
IPO Outlookprivate
Is Dyno Therapeutics going public?
No. Dyno Therapeutics is private and has not filed to go public. There is no S-1 on file.
What is Dyno Therapeutics' valuation in 2026?
Dyno Therapeutics is valued at $500M as of 2021-Q2, set by its Series A ($100M, May 2021). That is the last confirmed mark, not a live price — private shares do not trade continuously.
Has Dyno Therapeutics filed an S-1?
No public S-1 is on file for Dyno Therapeutics.
How much has Dyno Therapeutics raised?
Dyno Therapeutics has raised $111M in total, most recently a Series A of $100M in May 2021.
Is Dyno Therapeutics publicly traded — can you buy Dyno Therapeutics stock?
No. Dyno Therapeutics is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Dyno Therapeutics on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Founded
2018
HQ
Watertown, MA
Employees
92
Total Raised
$111M
Last Round
Series A — $100M (May 2021)
IPO Status
private
Fundraising Status
Series A · $100M · 5y 4mo ago
privateTotal raised $111M
Secondary Market
Implied price / share
$25.37
Last round price / share
$44.66
vs last round
-43.2%
Open interest
1
Last round price vs secondary price
Secondary price return by period
Implied per-share price from private secondary transactions, as of Jun 2026. This is a point estimate, not a quote — the feed carries no bid, ask or spread, and a secondary print is evidence of what someone paid on that date rather than a live market. Compare across every tracked name →
Latest Funding Round
Round
Amount
Date
Lead Investor
Post-Money
Series A
$100M
May 2021
—
$500M
Vertical Intelligence — Biotech / Gene Therapy
No name-verified sponsor record on ClinicalTrials.gov for Dyno Therapeutics — trials may run under a different legal entity, a partner sponsor, or not yet exist. Absence of a registry match is reported as-is, never guessed around.
Checked clinicaltrials.gov as of 2026-09-19. Re-checked weekly.
Talent Signal
Hiring trend
▶ Hiring steady
0% vs 2026-08
Open roles
3
via greenhouse
Product-build share
100%
engineering, research, product, design
Trajectory
steady
heavy product build — 100% of open roles are product-building functions (engineering/research/product) — 1 of 3 open roles are product.
Actively hiring with no tracked executive churn.
Open roles by month
Open roles by function
■ product-building ■ go-to-market / G&A
AI Product ManagerSr. Machine Learning Engineer - Machine LearningSr. Research Associate - Gene Therapy
Counted from Dyno Therapeutics's live job board as of 2026-09-14; role functions classified from posting titles. Open-role counts are an activity signal, not headcount. Refreshed monthly.
Biotechnology
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of 2021-Q2. Refreshed quarterly.